INCYTE CORP 4

Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp (INCY), was granted RSUs, performance shares, and stock options on July 16, 2026 as part of equity compensation, with no open-market buying or selling.

On July 16, 2026, Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp, received multiple equity compensation awards: 5,916 shares of common stock in the form of restricted stock units that vest 25% annually over four years, 14,790 performance share units that may result in up to 200% of one share of common stock each based on relative total shareholder return over a three-year period ending July 16, 2029, and stock options to purchase 25,538 shares of common stock at an exercise price of $116.65 per share, vesting 25% after one year and monthly thereafter over three years. These are routine equity incentive grants with no open-market purchases or sales, and following the awards Mayes holds 63,628 shares underlying RSUs plus additional performance shares and options, representing a substantial, primarily performance-based equity stake aligned with shareholder outcomes.

Filing Facts

CIK

879169

Ticker

INCY

Form

4

Source Type

fda

Accession

0002079962-26-000011

Alert Tier

5